Next report date
Report period
Q1 2024
EPS estimate
−1.62USD
Revenue estimate
—
−632.3380USD
−25.26 MUSD
4.85 M
About Panbela Therapeutics, Inc.
Sector
CEO
Jennifer K. Simpson
Headquarters
Waconia
Website
Employees (FY)
8
Founded
2011
FIGI
BBG0186G10C4
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PBLA is 0.4400 USD — it has increased by 7.29% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Panbela Therapeutics, Inc. stocks are traded under the ticker PBLA.
Panbela Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
PBLA stock is 18.05% volatile and has beta coefficient of 0.68. Check out the list of the most volatile stocks — is Panbela Therapeutics, Inc. there?
PBLA earnings for the last quarter are −53.80 USD per share, whereas the estimation was −41.20 USD resulting in a −30.58% surprise. The estimated earnings for the next quarter are −24.34 USD per share. See more details about Panbela Therapeutics, Inc. earnings.
Yes, you can track Panbela Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
PBLA stock has fallen by 12.00% compared to the previous week, the month change is a 29.03% fall, over the last year Panbela Therapeutics, Inc. has showed a 100.00% decrease.
PBLA net income for the last quarter is −6.47 M USD, while the quarter before that showed −7.83 M USD of net income which accounts for 17.33% change. Track more Panbela Therapeutics, Inc. financial stats to get the full picture.
Today Panbela Therapeutics, Inc. has the market capitalization of 2.14 M, it has decreased by 9.56% over the last week.
No, PBLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PBLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Panbela Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 8.00 employees. See our rating of the largest employees — is Panbela Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Panbela Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Panbela Therapeutics, Inc. stock shows the sell signal. See more of Panbela Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Panbela Therapeutics, Inc. future price: according to them, PBLA price has a max estimate of 25.00 USD and a min estimate of 5.00 USD. Read a more detailed Panbela Therapeutics, Inc. forecast: see what analysts think of Panbela Therapeutics, Inc. and suggest that you do with its stocks.